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Abstract
Background: Myocardial extravascular extracellular volume fraction (Ve) measures quantify diffuse fibrosis not
readily detectable by conventional late gadolinium (Gd) enhancement (LGE). Ve measurement requires steady state
equilibrium between plasma and interstitial Gd contrast. While a constant infusion produces steady state, it is
unclear whether a simple bolus can do the same. Given the relatively slow clearance of Gd, we hypothesized that
a bolus technique accurately measures Ve, thus facilitating integration of myocardial fibrosis quantification into
cardiovascular magnetic resonance (CMR) workflow routines. Assuming equivalence between techniques, we
further hypothesized that Ve measures would be reproducible across scans.
Methods: In 10 volunteers (ages 20-81, median 33 yr, 3 females), we compared serial Ve measures from a single
short axis slice from two scans: first, during a constant infusion, and second, 12-50 min after a bolus (0.2 mmol/kg
gadoteridol) on another day. Steady state during infusion was defined when serial blood and myocardial T1 data
varied <5%. We measured T1 on a 1.5 T Siemens scanner using a single-shot modified Look Locker inversion
recovery sequence (MOLLI) with balanced SSFP. To shorten breath hold times, T1 values were measured with a
shorter sampling scheme that was validated with spin echo relaxometry (TR = 15 sec) in CuSO4-Agar phantoms.
Serial infusion vs. bolus Ve measures (n = 205) from the 10 subjects were compared with generalized estimating
equations (GEE) with exchangeable correlation matrices. LGE images were also acquired 12-30 minutes after the
bolus.
Results: No subject exhibited LGE near the short axis slices where Ve was measured. The Ve range was 19.3-29.2%
and 18.4-29.1% by constant infusion and bolus, respectively. In GEE models, serial Ve measures by constant infusion
and bolus did not differ significantly (difference = 0.1%, p = 0.38). For both techniques, Ve was strongly related to
age (p < 0.01 for both) in GEE models, even after adjusting for heart rate. Both techniques identically sorted older
individuals with higher mean Ve values.
Conclusion: Myocardial Ve can be measured reliably and accurately 12-50 minutes after a simple bolus. Ve
measures are also reproducible across CMR scans. Ve estimation can be integrated into CMR workflow easily, which
may simplify research applications involving the quantification of myocardial fibrosis.
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Introduction
Emerging techniques in cardiovascular magnetic reso-
nance (CMR) offer new and important opportunities to
quantify pathologic myocardial fibrosis but require
further understanding to optimize their integration into
CMR workflow routines. Myocardial fibrosis, character-
ized by expansion of the myocardial extracellular matrix
and accumulation of interstitial collagen, is the hallmark
of pathologic remodeling [1]. This derangement alters
electrical and mechanical function. Extracellular col-
lagen, the principal constituent of the expanded extra-
cellular matrix [1], blocks electrical conduction [2-7],
constitutes the substrate for reentry and lethal ventricu-
lar arrhythmia [8], and stiffens the myocardium [1].
While CMR with late gadolinium enhancement (LGE)
can detect large macroscopic foci of myocardial fibrosis
[9], it cannot detect the full spectrum of myocardial
fibrosis. LGE relies on relative differences in signal
intensities expressed in arbitrary units and employs the
myocardium with lowest signal intensity as a reference
for normality, regardless of the degree of fibrosis con-
tained within. Two lines of evidence underscore a need
for alternative techniques beyond LGE. First, a recent
study indicated that collagen biomarkers were more sen-
sitive than LGE for detecting early myocardial fibrosis in
hypertrophic cardiomyopathy [10]. Second, roughly half
of the excess collagen in the setting of dilated cardio-
myopathy is deposited diffusely between myocytes as
opposed to focally [11], therefore undetectable by LGE.
Standard extracellular gadolinium (Gd) contrast tracks
collagen at the microscopic level with high fidelity with-
out an apparent critical mass needed for detection [12],
thereby offering an opportunity to use Gd concentration
as a robust indicator of myocardial fibrosis burden.
Indeed, recently developed methods [13-15] assess the
volume fraction of extravascular extracellular matrix
(Ve) in human myocardium (with standard contrast
agents) by exploiting the linear relationship between
change in relaxivity and Gd concentration. These meth-
ods, however, require steady state equilibrium between
the plasma and myocardial interstitium for successful
Ve measurement. Whether a lengthy continuous intra-
venous infusion is needed to achieve steady state, or
whether a simple bolus is sufficient to achieve steady
state equilibrium remains uncertain, but an important
issue for several reasons: First, introducing a lengthy
infusion imposes additional burden on patients and con-
siderable constraints on routine CMR workflow rou-
tines. Second, these data are important to interpret
results from studies employing either the bolus [13,15]
or infusion [14] techniques. Third, if the Gd dose
reserved for LGE is lowered (e.g., halving a 0.2 mmol/kg
dose to 0.1 mmol/kg bolus) [14] to allocate a portion
for the subsequent infusion, the sensitivity of LGE may
decline since doses as low as 0.1 mmol/kg have reduced
sensitivity for myocardial infarction [16].
Given the slow renal clearance of Gd, its low molecu-
lar weight, and rapid dispersion throughout tissues
[17,18], we tested whether a simple bolus permits accu-
rate Ve measurement. We hypothesized that the equili-
brium between plasma and the interstitium contrast
concentrations would be maintained during slow renal
clearance so that the ratios of Gd in myocardium and
blood, the change in their respective relaxivities, and Ve
would remain constant and similar to measures acquired
during steady state infusion. If indeed Ve measurement
was not related to technique, we further hypothesized
that Ve measures would also be reproducible between
scans. We compared the accuracy of serial Ve measures
from two different CMR scans (at 1.5 T) in each subject,
the first involving a continuous infusion to demonstrate
the attainment of steady state equilibrium, and the sec-
ond involving a simple intravenous bolus as is typically
performed for LGE imaging.
Methods
T1 and T2 Measurement in Phantoms
CMR-based Ve measurement requires robust measure-
ment of T1. Therefore, we compared 2 different meth-
ods of T1 measurement in phantoms with varying
concentrations of CuSO4 and Agar to produce similar
T1 and T2 of myocardium and blood, before and after
Gd administration. Physiologic T2 values are important
for sequences with steady state free precession readouts
because signal intensity varies by T2/T1. All measure-
ments were acquired with a 1.5 Tesla Siemens Magne-
tom Espree (Siemens Medical Solutions, Erlangen,
Germany) with a 32 channel phased array cardiovascular
coil. To obtain T1 values from CMR data, we used a 3
parameter model to describe signal intensity (SI) as a
function of inversion time (TI): SI = | A - B·e(-TI/T1*) |,
where T1 = T1*((B/A)-1) [19]. T2 values were obtained
using a 2 parameter model describing SI as a function
of echo time (TE): SI = A·e(-TE/T2). Least square esti-
mates of model parameters were obtained using the
Levenberg-Marquardt algorithm in Matlab® (The Math-
Works, Inc., Natick, Massachusetts).
T1 and T2 Relaxometry
For a reference standard, T1 was measured by spin echo
inversion recovery experiments, acquiring 1 k-space line
per readout (i.e., echo train = 1), TR = 15 s, TE = 10
msec, FA 90 degrees, with 10 inversion times ranging
from 25 - 8000 msec. T2 was measured by spin echo
experiments, acquiring 1 k-space line per readout, TR =
15 s, FA 90 degrees, with 10 TE times ranging from
10 - 400 msec.
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T1 using MOLLI
We measured T1 using an ECG-gated single-shot modi-
fied Look Locker inversion recovery (MOLLI) sequence
as described by Messroghli et al. [20] with simulated
heart rates. Typical parameters were FOV 360 ×
270 cm, matrix 256 × 128, 6 mm thickness, FA 35
degrees, 6/8 partial Fourier k-space sampling, parallel
processing factor (GRAPPA) 2, and initial effective inver-
sion time (TIeff) 90 msec with a TIeff increment of 80
msec. To sample T1 recovery, serial single shot diastolic
images were acquired every heart beat after 3 nonselec-
tive adiabatic inversion pulses (i.e., 3, 3, and 5 images
after each inversion pulse, totaling 11 images), and 3
dummy heart beats separated inversion pulses [20]. We
refer to this sampling approach as “Classic MOLLI.”
We also used a shorter sampling scheme to minimize
breath hold times. A shorter sampling scheme may also
minimize potential T1 measurement error due to effects
related to repeated excitations prior to complete recov-
ery of magnetization between serial inversion pulses. For
longer precontrast T1 recovery of myocardium and
blood (~950 and 1500 msec, respectively), we adjusted
the above sampling scheme to employ only 2 nonselec-
tive adiabatic inversion pulses with a 5 and 1 sampling
scheme (6 images total).
For post contrast T1 recovery that demonstrates faster
relaxation rates, we employed 3 inversion pulses with a
4, 2, and 1 sampling scheme (7 images total). This
approach attempted to ensure adequate sampling of the
initial portion of the T1 recovery curve where the rate
of relaxation was highest given the constraints imposed
by sampling limited to diastole. Hence, additional data
points were sampled during early T1 recovery for post
contrast T1 measures. Furthermore, in contrast to pre-
contrast sampling, we reasoned that the sample from 5th
heart beat was unnecessary because most post contrast
T1 values were approximately 500 msec or less, mean-
ing that 99% of the magnetization had recovered by four
heart beats (i.e., 2.5 sec, or 5 multiples of post contrast
T1 if the R-R interval was ≥625 msec). We refer to this
overall shortened T1 sampling approach adapted to the
anticipated precontrast or post contrast T1 recovery
curve as “Hybrid MOLLI.” Using “Classic” and “Hybrid”
MOLLI, we compared T1 data from phantoms against
the spin echo derived values at slower (68 bpm) and fas-
ter simulated heart rates (92 bpm). Each of the 7 phan-
toms had 5 measurements by each MOLLI technique.
Monte Carlo Simulation
To explore how variable sampling of the T1 recovery
curve affected the precision of T1 measures, we used
Monte Carlo simulations to compare the root mean
square error associated with the “Classic” and “Hybrid”
sampling schemes mentioned above. Importantly, this
simulation did not measure effects related to incomplete
magnetization recovery between serial excitation pulses
(whereas the phantom studies did), and thus was not
used to assess accuracy. For simulation, we assumed a
maximum signal amplitude (A.U.) of 250 and added
noise with a standard deviation of 10. We performed
128 trials for each set of parameters, varying the heart
rate from 50-100 beats per minute (5 bpm increments)
and sampled T1 ranges from 200-500 msec and
800-1500 msec (100 msec increments).
Subjects
After Institutional Review Board approval and written
informed consent, ten volunteers received CMR exams.
Six were young adults who were under age 35, healthy,
without symptoms or known comorbidity. Since renal
function declines with age [21], these young subjects
represented those with the highest renal function, fastest
Gd clearance, and thus the greatest potential to disrupt
equilibrium (and also Ve measures) after a bolus. Data
were also acquired from four older subjects with ages
ranging from 66-81 years, all clinically stable and asymp-
tomatic, but with significant comorbidity. These older
subjects represented those with a potential to disrupt
equilibrium not from robust renal clearance, but from
1) a larger volume of distribution for Gd contrast, and
2) less capillary density [22-24] which occurs with older
age and associated comorbidity. Together, the larger
interstitial reservoir for Gd to accumulate and the dimin-
ished capillary density might prevent steady state equili-
brium between plasma and myocardium after a bolus.
T1, lambda, and Ve measurement in Subjects
Infusion
We modified the intravenous infusion protocol outlined
by Thornhill et al. [25] to constrain the total contrast
dose to be 0.2 mmol/kg. For the infusion CMR scan, we
gave a loading dose (0.1 mmol/kg gadoteridol bolus
(Prohance, Bracco Diagnostics, Princeton, NJ)) followed
by a 200 mL/hr infusion for ~1 hr with 0.1 mmol/kg
diluted in 200 mL saline. Assuming a baseline myocar-
dial blood flow of ~1 mL/g/min and an extraction
efficiency of 0.6, this strategy should attain plasma-
interstitium equilibrium for a wide range of Ve by ~25
minutes [26]. We arrived at the final infusion protocol
by further iterative adjustments in 4 additional volun-
teers. T1 measures were obtained precontrast and repe-
titively during the 1-hour period after the initiation of
contrast infusion. We defined steady state equilibrium
during infusion when T1 values of both blood and myo-
cardium varied by <5% [14].
Bolus
For the bolus CMR scan acquired on a different day,
subjects received a 0.2 mmol/kg intravenous bolus of
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gadoteridol. T1 measures were obtained precontrast and
repetitively during the 12-50 min period after the receipt
of the contrast bolus. We delayed Ve measurement for
12 minutes after the bolus to ensure full dispersion and
equilibration of Gd contrast between tissues, which
occurs after at least 5 minutes [13].
Ve measurement
We measured Ve as outlined by Jerosch-Herold et al.
[13] Specifically,
Ve 1-hematocrit Vp= ⋅ ⋅ ( )⎡⎣ ⎤⎦  –
where Ve is the myocardial extravascular extracellular
volume fraction, r is the specific density of myocardial
tissue (1.05), Vp is the myocardial plasma volume
fraction (assumed to be a constant 0.045 [13,27-29],
reflecting capillary density), and l=[ΔR1myocardium]/
[ΔR1bloodpool] pre and post Gd contrast (where R1 = 1/
T1) [30,31]. Hematocrit was measured from blood sam-
ples drawn at the time of each CMR session. We carefully
localized one mid ventricular short axis slice per subject
for T1 measurement to match slice position across differ-
ent scans. Blood pool regions of interest were intention-
ally large to average any inhomogeneity related to
diastolic blood flow. Images were analyzed with Siemens
multimodality workstations. When drawing circumferen-
tial regions of interest in the myocardium with computer
assisted planimetry, care was taken to avoid the very
edges of myocardium to avoid contaminating the mea-
surement with partial volume averaging from voxels
straddling the myocardial-blood pool border [12].
Late Gadolinium Enhancement
We acquired late gadolinium enhancement images
10-30 minutes after the 0.2 mmol/kg gadoteridol bolus in
all subjects in the usual fashion [32]. To optimize detec-
tion of grossly evident scar or myocardial infarction, we
used a phase sensitive segmented gradient echo inversion
recovery [33] pulse sequence to increase signal to noise
ratios, correct for surface coil intensity variation, and ren-
der signal intensity proportional to T1 recovery.
Statistical Analysis
T-tests compared continuous variables. Linear regres-
sion compared the mean Ve for subjects (given unequal
number of measurements for bolus and infusion)
according to measurement technique; Bland-Altman
plots assessed overall agreement and bias between Ve
measurement techniques [34]. Generalized estimating
equations (GEE) with exchangeable correlation matrices
to account for serial measures compared the linear
regression slopes of individual classic and hybrid
MOLLI T1 measurements against spin echo T1 mea-
surements. GEE also summarized any differences
between the infusion (at steady state equilibrium) and
bolus techniques for Ve measurement, adjusting for
repeated Ve measures across individuals over time. To
assess for an interaction between time and Ve measures,
a time variable and a variable representing the product
of Ve and time was entered into the model. Analyses
were performed using SAS (Cary, NC) and Microsoft
Excel (Redmond, Washington).
Results
Monte Carlo Simulation
Monte Carlo simulation revealed no difference in the
root mean square error (RMSE) between classic and
hybrid MOLLI for T1 values between 200-500 msec
(RMSE 14 vs. 14, p = 0.51, paired t test). At higher T1
values of 800-1500 msec, classic MOLLI exhibited better
precision than hybrid MOLLI (RMSE 29 vs. 45, respec-
tively, p < 0.001). It should be noted that this simulation
scheme did not account for effects related to repeated
excitation pulses as did the phantom data below.
Phantom Studies
Phantom T1 and T2 values measured by spin echo
relaxometry closely approximated the expected range of
physiologic values before and after contrast administra-
tion. The phantom representing blood before contrast
had T1/T2 values of 1535 msec/172 msec. Two precon-
trast myocardium phantoms had T1/T2 values of 909
msec/44 msec and 887 msec/38 msec. Postcontrast
blood phantoms had T1/T2 values of 309 msec/187
msec and 251 msec/171 msec. Postcontrast myocardial
phantoms had T1/T2 values of 342 msec/53 msec and
260 msec/53 msec.
Correlation plots and Bland-Altman analysis demon-
strated that hybrid MOLLI exhibited better agreement
with spin echo T1 relaxometry measures than classic
MOLLI. At a relatively low heart rate of 68 bpm, serial
T1 measures (5 repetitions per phantom for each tech-
nique; thus 70 total measures) by ECG gated MOLLI
were highly correlated with the spin echo ‘gold standard’
measures (Figure 1). The regression line for hybrid
MOLLI had a slope of 0.98 (95%CI 0.91-1.06), that was
not significantly different from unity (p = 0.66). In con-
trast, the regression line for classic MOLLI had a slope
of 0.95 (95%CI 0.91-0.99), significantly less than unity
(p = 0.007). These differences were more pronounced at
higher heart rates (i.e., 92 bpm) where the regression
line slopes for hybrid and classic MOLLI were 0.95
(95% CI 0.89-1.01; p = 0.12) and 0.88 (95% CI 0.87-0.89;
p < 0.001), respectively. At higher heart rates, Bland-
Altman analysis revealed that the classic MOLLI
approach underestimated T1 when T1 was long but
overestimated T1 when T1 was short. This bias com-
presses the dynamic range of the T1 differences. Hybrid
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MOLLI exhibited less bias and generally yielded better
agreement.
Both the hybrid and classic MOLLI acquisitions
demonstrated excellent reproducibility for repeated mea-
surements. The coefficients of variation for all phantoms
were <1.6%. At a heart rate of 68 bpm the mean coeffi-
cient of variation was 0.55% and 0.59% for hybrid versus
classic MOLLI, respectively; at a heart rate of 92 bpm
the mean coefficient of variation was 0.53% and 0.61%
for hybrid versus classic MOLLI, respectively. The coef-
ficients of variation for each phantom measured by
either technique are plotted as a function of T1 for both
a slow and faster heart rate in Figure 2. Given the better
correlation and agreement with T1 measurement com-
pared to the spin echo gold standard as well as the com-
parable precision in phantom studies (but not
Figure 1 Comparison of “Classic” MOLLI (i.e., 3+3+5 uniform sampling scheme) and “Hybrid” MOLLI (i.e., 5+1 precontrast or 4+2+1
post contrast sampling scheme) with spin echo T1 measures (gold standard) in CuSO4-Agar phantoms with T1 and T2 values similar
to myocardium and blood before and after contrast (see text for details). Both exhibit excellent correlation with spin echo measures.
“Hybrid MOLLI” exhibits slightly better correlation (panels A and B) and better agreement with less bias (panels C and D) compared to “classic”
MOLLI (Panels E and F), especially at higher heart rates. Each of the 7 phantoms had 5 serial measurements.
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simulation studies), hybrid MOLLI techniques were
selected for T1 measurement in human subjects as
demonstrated in Figure 3.
Subjects
Median age of the 10 subjects was 33 years (range 20-81
yrs), and 3 were female. All subjects were free of cardiac
symptoms. Characteristics of the subjects are shown in
Table 1. The six younger subjects were healthy without
any associated comorbidity. No subject exhibited
abnormalities on late gadolinium enhancement images
in the slice position used for Ve measurement; one sub-
ject with a history of myocardial infarction exhibited
late gadolinium enhancement remote from myocardium
used for Ve measurement.
Representative images used for T1 measurement are
shown in Figure 3. Signal intensity versus inversion time
plots indicate good fit to the T1 recovery curves. Post
contrast T1 curves for blood and myocardium indicate
magnetization has nearly completely recovered after 4
heart beats (hence the 4+2+1 “hybrid” post contrast
sampling scheme). Before contrast, 5 heart beats are
needed to sample the full span of the longer T1 recov-
ery curve.
Older subjects had higher mean Ve from infusion
compared to younger subjects under age 35 (21.1 ±
1.1% vs. 25.3 ± 2.4% by the infusion technique and 20.8
± 1.8% vs. 25.2 ± 2.1% by the bolus technique, respec-
tively; p ≤ 0.03 for both). Similarly, for each technique,
regression analysis of mean Ve values for each subject
also yielded a significant relation between Ve and age
regardless of whether the infusion technique or the
bolus technique was employed (Figure 4). Because heart
rate may exert slight effects on T1 measurement by
MOLLI, we created a multivariable GEE regression
model that adjusted for heart rate. Regardless of techni-
que, Ve remained significantly related to age (p < 0.01
for both), even after adjusting for heart rate which was
not significant predictor (p ≥ 0.2). Whether high Ve
values were related to age alone or associated comorbid-
ity or both is beyond the scope of this work.
Comparison of Ve Measurement by Infusion and Bolus
Techniques
Baseline precontrast T1 measures for the “infusion” scan
and the “bolus” scan permit assessment of T1 variability
across scans. There was no significant difference
between T1 measures of blood (1534 vs. 1502 msec, p =
0.41) and myocardium T1 (946 vs. 948 msec, p = 0.83).
Yet, the median of the absolute value of T1 differences
in individual subjects between the scans was 20 msec
for myocardium (2.1% of mean myocardial T1) and 55
msec for blood (3.6% of mean blood T1), indicating
variability attributable solely to T1 measurement
between scans. This precontrast T1 variation across two
scans was greater than T1 variation within one scan. For
the infusion scan, precontrast blood and myocardium
T1 were measured twice. The median of the T1 differ-
ences in individual subjects for an extra T1 measure-
ment during the infusion scan was 12 msec for
myocardium (1.3% of mean myocardial T1) and 20 msec
for blood (1.3% of mean blood T1), indicating the varia-
bility of T1 measures within one scan.
Despite the variability in precontrast T1 measure-
ments, Ve data from both methods (i.e., during continu-
ous infusion with steady state defined by stable blood
and myocardial T1 and after a simple bolus) yielded
similar results. Because the clearance of Gd contrast is
slow relative to its equilibration between tissues, both
T1 and the ΔR1 changed gradually, and the partition
coefficient, l, remained constant. The stability of infu-
sion- and bolus-based Ve estimation is illustrated in
Figure 5. This observation would only occur if steady
state between interstitium and plasma was maintained
Figure 2 Coefficients of variation for phantoms measured by “Classic” MOLLI and “Hybrid” MOLLI techniques (see text for details).
Both techniques exhibit excellent reproducibility (<2%), but the hybrid MOLLI technique exhibits more precision at higher T1 values.
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Figure 3 Representative T1 values of myocardium and blood in a subject before and after contrast can be measured with a modified
Look Locker pulse sequence employing single shot SSFP imaging within a single breath hold. Signal intensities are plotted against
effective inversion time. A three parameter fitting of the data with a correction for read-out attenuation yields T1 values (see text for details). The
top panel shows myocardial T1 curves before and after contrast whereas the lower panel shows the blood T1 curves before and after contrast.
Most of the magnetization recovers after 4 heart beats after contrast administration. Pre and post contrast thumbnails corresponding to the
myocardium and blood pool data points in the curves are also shown in order of effective inversion times.
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Table 1 Characteristics of subjects undergoing assessment of the extravascular extracellular volume fraction (Ve)
Age Gender Comorbidity Mean Infusion
l (SEM)
Infusion
hematocrit (%)
Mean Bolus l
(SEM)
Bolus
hematocrit (%)
20 male none 0.452 (0.002) 47.7 0.424 (0.007) 46.1
21 male none 0.399 (0.002) 41.2 0.392 (0.004) 41.9
21 female none 0.434 (0.004) 39.6 0.424 (0.004) 38.9
22 male none 0.398 (0.002) 41.0 0.401 (0.003) 42.1
31 male none 0.412 (0.002) 40.4 0.424 (0.003) 42.3
34 male none 0.437 (0.001) 42.7 0.448 (0.002) 41.5
66 female Ulcerative colitis, colectomy, diabetes, left bundle branch
block, recurrent infections
0.451 (0.002) 30.0 0.442 (0.002) 29.8
68 female Diabetes, obesity, hypertension 0.453 (0.002) 38.0 0.461 (0.003) 38.9
69 male Myocardial infarction, hypertension 0.473 (0.006) 44.4 0.474 (0.009) 44.0
81 male Atrial fibrillation 0.460 (0.002) 41.2 0.459 (0.004) 40.4
Subjects were either healthy young adults or older individuals with significant comorbidity.
Figure 4 The Ve spectrum in volunteers by age was similar regardless of technique. As expected, Ve values were significantly higher in
older subjects with significant comorbidity. Ve data from either the infusion technique (Panel A) or the bolus technique (Panel B) yielded similar
linear regression results where both techniques detected significantly higher Ve with increasing age. When the same Ve data were then sorted
in order of ascending Ve (sorted by Ve from infusion technique in Panel C; sorted by Ve from bolus technique in Panel D), both techniques
identically sorted the older subjects with higher mean Ve (dashed boxes). Error bars in the bar graphs indicate the standard error of the mean
for repeated Ve measures by each technique in each individual.
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during the clearance of gadolinium contrast. Of note,
this 68 year old subject had excellent renal function
with a serum creatinine of 0.8 and a preserved glomeru-
lar filtrate rate of 71 mL/min/1.73 m2.
With the infusion technique, the range of individual
Ve measures among subjects was 19.3%-29.2% with a
SD≤0.9% for repeated measures (n = 110) in the 10 sub-
jects. Similarly, the range of individual Ve measures
among subjects measured by the bolus technique was
18.4%-29.1%, with a SD≤1.3% for repeated measures (n
= 95). In GEE regression models that adjusted for the
clustering of repeated measurements in subjects, serial
Ve measures by bolus or infusion did not differ
significantly (Ve difference between techniques = 0.1%,
p = 0.38). Moreover, when the mean Ve for each subject
measured by bolus was plotted against the mean Ve
measured by infusion, the regression line had a slope
similar to unity, an intercept of nearly zero, and a high
R2 value (Figure 6). Importantly, Bland-Altman plots did
not reveal significant bias introduced by the bolus tech-
nique. Given the lack of a statistically significant differ-
ence in Ve measurements related to technique, Ve
measurements across CMR scans were therefore
reproducible.
The variation between the techniques was similar to
the variation within each technique. As shown in the
Figure 5 Ve measurements in a 68 year old female subject with diabetes and hypertension remain constant over time with a constant
infusion or with a bolus. Panel A shows T1 values for blood and myocardium during a constant infusion; the T1 values with associated Ve
measures become level and remain relatively constant with <5% variation. Panel B, however shows ever increasing T1 values following a single
bolus as gadolinium contrast is cleared. Yet the Ve data (expressed as a proportion, green triangles) yield similar mean Ve values (green line) for
each technique. In Panels C and D, the same data (for infusion and bolus, respectively) are expressed as the change in relaxivity (delta R1) which
linearly relates to gadolinium contrast concentration. T1 and delta R1 do not change rapidly indicating relatively slow clearance. As such, it
becomes evident that the ratio of myocardial delta R1 to blood delta R1–the principal determinant of Ve, after adjustment for the hematocrit–
remains constant. The ratio is expressed as the partition coefficient lambda (expressed as a proportion, green circles with the green dotted line
represents the mean lambda). Indeed, the Ve measures for both the infusion and bolus techniques remain nearly constant at 0.25 (right vertical
axis). This finding demonstrates steady state equilibrium between plasma and the myocardial interstitium even as the T1 changes in both tissues
during the slow renal clearance of contrast.
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Bland-Altman plots, the 95% confidence intervals of ±
1.2% for difference between mean Ve measures by bolus
versus infusion in the were similar to the 95% confi-
dence intervals for repeated measures by either techni-
que. The average 95% confidence interval for Ve
measured by infusion was ± 1.0%, and the average 95%
confidence interval for Ve measured by bolus was ±
1.4%. Finally, we detected a very small, but statistically
significant (p < 0.001) interaction between time and Ve
measurement after a bolus. Ve increased slightly by
0.6% over 30 minutes, which was well within the 95%
confidence intervals for serial Ve measurements by
either infusion (± 1.0%) or bolus (± 1.4%) as shown in
Figure 6. There was no time interaction for Ve measures
by the constant infusion technique (p = 0.17).
Discussion
The bolus technique simplifies Ve measurement in
humans. With the MOLLI-based T1 computation, Ve
can be measured with a simple Gd contrast bolus as
accurately as with an infusion, but with slightly less pre-
cision, i.e., ± 0.4% absolute difference in the 95% confi-
dence intervals for Ve. Steady state equilibrium is
achieved with both methods as evidenced by the stable
Ve measures, even as the Gd contrast concentrations
changes slowly in myocardium and blood from renal
clearance. While we did detect a small, statistically sig-
nificant time interaction with the bolus technique, the
magnitude of the time interaction was well within the
95% confidence intervals for Ve measurement by either
technique and therefore of questionable clinical signifi-
cance. Indeed, both methods could easily sort the sam-
ple and robustly identify the order of the higher Ve
values in older subjects with significant comorbidity,
even in the absence of evident late gadolinium enhance-
ment. Since Ve measures obtained from scans per-
formed on different days were not significantly different,
Ve measures are therefore reproducible.
The importance of myocardial fibrosis in heart disease
has been recognized for decades [1]. A variety of studies
indicate that myocardial fibrosis generally represents a
final common pathway to a variety of insults [11,35-37].
As such, the human validation study recently published
by Flett et al. [14] provides an important tool to those
investigating the role of the “interstitial heart disease.”[1]
Their study established that quantitative Ve measures
correlate highly with picrosirius red measures of the col-
lagen volume fraction. Others who employed a bolus
strategy for Ve measurement have also shown that Ve
values are abnormal in defined patient populations
[13,15].
Our work highlights the validity of these previously
reported Ve measures based on a bolus strategy [13,15].
We demonstrate that Ve measures are reproducible and
reasonably precise from scan to scan with good confi-
dence intervals for Ve estimates, regardless of whether a
bolus or infusion technique is employed. We also
observe that the range of our Ve data from healthy con-
trols (21.1 ± 1.1% vs. 25.3 ± 2.4% by the infusion techni-
que, and 20.8 ± 1.8% vs. 25.2 ± 2.1% by the bolus
technique for young healthy versus older with comor-
bidity, respectively; p ≤ 0.03 for both) were remarkably
similar to the Ve range in controls (mean age was 45
years) reported by Jerosch-Herold et al. [13] (24% ± 3%
vs. 31% ± 5% for unaffected family members vs. patients
with idiopathic dilated cardiomyopathy, p = 0.002).
Similarly, by transforming the “fibrosis index” reported
by Broberg et al. [15] to Ve values [where fibrosis index
Figure 6 Correlation and Bland-Altman plots of mean Ve measures for each of the ten subjects by infusion or bolus techniques. Ve
measures by either technique are highly correlated without evidence for significant bias. The correlation plot includes bars representing the
mean Ve ± standard error for each subject by bolus or infusion. Bland Altman analysis depicts the mean difference between the bolus or
infusion technique (solid line) ± 1.96 SD (dotted lines). The 95% confidence intervals of ± 1.2% for the mean Ve difference between bolus and
infusion techniques in Bland Altman analysis are comparable to the average 95% confidence intervals for repeated Ve measures by infusion
alone (± 1.0%) or by bolus alone (± 1.4%).
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= l·(1-hematocrit)], we find that healthy controls from
this study had Ve values of 21.5% ± 2.1%. Therefore,
normal Ve values appear to be approximately 25% or
less, but further work is needed to ascertain “normality”
for Ve measures. Note, the only difference between Ve
as computed both in our manuscript as well as the
manuscript by Jerosch-Herold et al. [13] compared to
the “myocardial volume of distribution” described by
Flett et al. [14] or the “fibrosis index” described by Bro-
berg et al. [15] is that the Ve measure simply multiplies
these latter measures by the specific density of myocar-
dium, r (1.05), and then subtracts the plasma volume
fraction in myocardium which is assumed to be constant
at 4.5%.
The bolus strategy to measure myocardial Ve simpli-
fies the Ve data acquisition protocol and facilitates its
integration into routine CMR practice. We believe these
features will accelerate investigation in the role of the
interstitium in health and disease by minimizing the
burden on patients and investigators imposed by Ve
assessment. Furthermore, the reproducibility of Ve mea-
sures between CMR scans is important for studies
examining factors that affect changes in Ve over time (e.
g., as a result of intervention).
In support of our conclusions, Thornhill et al. also
found similar results for partition coefficients of infarcted
and noninfarcted myocardium measured with either a
constant infusion technique or a simple bolus [25]. Our
work builds on their results in several ways. First, we
used Ve as a myocardial extravascular extracellular space
marker which is inherently more accurate than partition
coefficients since the latter vary significantly as a function
of hematocrit for a given Ve as shown graphically in
Figure 7. Similarly, for a measured partition coefficient,
the resultant Ve will depend on the hematocrit (Figure
7). Thus, hematocrit variation will confound myocardial
fibrosis comparisons across subjects if partition coeffi-
cients (or even T1 measures) are employed as surrogate
fibrosis measures. Second, we measured the partition
coefficient and Ve using actual T1 measurements as
opposed to signal intensity surrogates (which do not vary
linearly with Gd concentration) generated from pulse
sequences (spoiled gradient echo) with lower signal to
noise ratios than SSFP [38]. Third, we employed a statis-
tical modeling approach to adjust for clustering of non
independent repeated measures in subjects and also iden-
tify subtle time interactions. Lastly, we studied a funda-
mentally different population with a narrower spectrum
of myocardial disease characterized by more subtle
degrees of myocardial remodeling than frank myocardial
infarction. Still, we were nonetheless able to identify
higher Ve values from older individuals with comorbidity
as compared to the lower Ve values from younger healthy
subjects with without known comorbidity.
Ve measurement techniques have been developed spe-
cifically to quantify the full spectrum of myocardial
fibrosis, including diffuse fibrosis not detectable with
conventional LGE images that may be difficult to distin-
guish from background noise [13-15]. Even though none
of the subjects exhibited enhancement in the myocar-
dium used for Ve measurement, both techniques identi-
cally stratified older individuals with higher comorbidity
based on the higher Ve in older subjects with comorbid-
ity. Although not the primary aim of this study, this spe-
cific finding is important because it confirms the
remarkably robust ability of CMR to detect age-related
Figure 7 Hematocrit exerts a significant influence on the relationship between Ve and the partition coefficient, l. Ve (expressed as a
percentage) is defined here as the following: Ve = [l · (1-hematocrit) · r] - Vp where Ve is the myocardial extravascular extracellular volume
fraction, r is the specific density of myocardial tissue (1.05), Vp is the myocardial plasma volume fraction (assumed to be a constant 0.045,
reflecting capillary density), and l=[ΔR1myocardium]/[ΔR1bloodpool] expressed as a decimal). Since anemia is common in various conditions (e.g.,
heart failure), obtaining the hematocrit is essential for accurate Ve measurement. Panel A shows how l will vary nonlinearly with the hematocrit
for a range of Ve values. Similarly, panel B shows how Ve will vary inversely with the hematocrit for a range of l values.
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change in the interstitium directly, in the absence of
frank LGE. Other noninvasive techniques lack this cap-
ability. Thus, CMR can demonstrate a spectrum of
interstitial changes within the myocardial interstitium
itself that otherwise remain unappreciable with conven-
tional imaging techniques. We believe Ve measures will
provide an important tool to investigate the relationship
between age, myocardial fibrosis, and other age-related
changes described previously [23,24,39-41].
Accurate Ve measurement relies heavily on robust T1
measurement. MOLLI techniques with balanced steady
state free precession (SSFP) are excellent methods to
measure the T1 of myocardium and blood before and
after contrast from which Ve is calculated. Use of this
pulse sequence yielded excellent agreement to T1 values
as measured by spin echo relaxometry at both slower
and faster heart rates. Our sampling scheme of the T1
recovery curve intentionally used fewer data points for
T1 curve fitting than others [13,20,30]. We attempted to
minimize breath hold time for human subjects and also
minimize disturbing the recovery of magnetization after
inversion pulses by 1) minimizing repetitive inversion
pulses generated prior to complete T1 recovery, and 2)
minimizing repetitive sampling of the magnetization
vector which can lead to systematic errors [42]. In fact,
the shorter “hybrid MOLLI” scheme that we employed
for Ve measurements in human subjects was based
upon better accuracy and precision for T1 measurement
in phantoms than the conventional T1 sampling scheme
[20]. We note that Piechnik et al. who also have recog-
nized the limitations of “classic MOLLI” have recently
published similar accuracy data whereby shorter MOLLI
sampling schemes are less heart rate dependent [43].
We also note that their “conditional” T1 sampling
approach is conceptually similar to the “hybrid MOLLI”
technique whereby sampling is adapted to T1 curve.
We attempted to minimize disturbance of the magne-
tization vector recovery by employing balanced SSFP.
Compared to other T1 measurement techniques that
employ spoiled gradient echo readouts, balanced SSFP
offers higher signal to noise ratios and minimal distur-
bance of the magnetization vector that may produce sys-
tematic errors in T1 measurement, especially at higher
heart rates [19,42]. In addition, SSFP is less susceptible
than gradient echo to flow artifact in the blood pool
[38] which can also perturb T1 measurements. Indeed,
the magnitude of variation in precontrast T1 blood
values was not much larger than the variation in pre-
contrast myocardium T1 values. Moreover, MOLLI data
can be obtained in a single breath hold, rendering the
acquisition fast and patient friendly. In contrast, seg-
mented T1 measurement techniques require 7-8 breath
holds per T1 measurement [14]. If an individual is
unable to breath hold, MOLLI images can still be
obtained without respiratory motion ghosting artifact
typical of segmented images (but potentially at the
expense of through plane motion). This feature is parti-
cularly important in the setting where arrhythmia is pre-
sent or where patient comorbidity prevents successful
breath holding. Unlike segmented T1 measurement
techniques [14], MOLLI can be applied to the full spec-
trum of patients, regardless of comorbidity, thus avoid-
ing potential selection biases. Nonetheless, efforts to
optimize T1 measurement strategies upon which Ve is
based continue to evolve [43].
Our work has some limitations. First, we could not
obtain histologic validation to corroborate our Ve mea-
sures because our subjects had no indication for heart
surgery or endomyocardial biopsy. Nonetheless, Flett et
al. have previously demonstrated excellent correlation of
Ve values with the collagen volume fraction in human
subjects [14]. They used a different method to measure
T1, but we have demonstrated that our T1 measures
agree very well with meticulous T1 relaxometry mea-
sures obtained from phantoms with representative T1
and T2 values. Second, to compare bolus versus infusion
Ve measures, we also did not sample the entire spec-
trum of myocardial remodeling as evidenced by the
absence of late gadolinium enhancement abnormalities
in our subjects. We cannot exclude that individuals with
very large areas of fibrosis/necrosis with low capillary
density might not exhibit steady state pharmacokinetics
with a bolus. Yet, Thornhill et al. did not find evidence
of different partition coefficients measured with either
bolus or infusion techniques within the extremes of
grossly infarcted myocardium or apparently normal
myocardium [25]. Thus, we believe the simple bolus
strategy is valid across the fibrosis spectrum, with one
notable exception: systemic amyloidosis. This condition
is characterized by marked interstitial expansion from
deposition of amyloid proteins and very rapid, presum-
ably extrarenal clearance of Gd contrast from the blood
pool [44], and we suspect that a bolus might not yield
accurate Ve measures under such conditions. Third, we
did not measure renal function in some of the younger
subjects although there was no indication of renal
impairment. Fourth, our Ve measures excluded the
edges of the myocardium due to concerns about partial
volume error in the setting of limited spatial resolution
[12]. This approach will not detect fibrosis limited to
the subendocardium or subepicardium. Myocardial
fibrosis in nonischemic cardiomyopathy is a generally
diffuse process [11], but ischemic cardiomyopathy
demonstrates more fibrosis in the subendocardium [36].
Lastly, we, like other investigators [13-15], did not
account for any variation in myocardial plasma volume
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fraction (Vp) across individuals; this issue requires
further study using additional techniques beyond the
scope of this manuscript.
Conclusions
Ve measurement did not differ significantly between
techniques employing a simple contrast bolus or a smal-
ler bolus followed by a lengthy infusion to demonstrate
steady state. Both methods identified similarly strong
relationships between Ve and age. Both methods could
easily sort the study sample and robustly identify the
order of the higher Ve values in older subjects. Ve mea-
sures were also reproducible since we could not identify
a statistically significant difference between Ve measures
from different scans. Because the bolus strategy simpli-
fies Ve measurement, these data may facilitate integra-
tion of Ve measurement into routine CMR practice.
This strategy may accelerate investigation of the role of
Ve in health and disease by avoiding the burden
imposed by an infusion on patients and investigators.
The reproducibility of Ve measures across scans is also
important for studies examining changes in Ve
measures.
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